Efficacy of Oral Famotidine and 2 Omeprazole Formulations for the Control of Intragastric pH in Dogs

Journal of Veterinary Internal Medicine

Volumn 25, Issue 1, 2011, Pages 47-54

  Tolbert, K ^a   Bissett, S ^a   King, A ^a   Davidson, G ^a   Papich, M ^a   Peters, E ^b   Degernes, L ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Acid disorders; Gastroenterology; Gastrointestinal

Indexed keywords

ANTIULCER AGENT; FAMOTIDINE; OMEPRAZOLE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DRUG EFFECT; FEMALE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PH; RANDOMIZED CONTROLLED TRIAL; STOMACH; STOMACH PH; TELEMETRY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DOGS; FAMOTIDINE; FEMALE; GASTRIC ACIDITY DETERMINATION; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; STOMACH; TELEMETRY;

CANIS FAMILIARIS;

EID: 78651227717     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2010.0651.x     Document Type: Article

References (27)

1. Wallmark B, Larsson H, Humble L. The relationship between gastric acid secretion and gastric H+, K+-ATPase activity. J Biol Chem 1985;260:13681-13684.
2. Hartmann M, Ehrlich A, Fuder H, et al. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther 1998;12:1027-1032.
3. Larsson H, Carlsson E, Junggren U, et al. Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterology 1983;85:900-907.
4. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51 (Suppl 1):59-67.
5. Papich M. Papich M. Saunders Handbook of Veterinary Drugs, 2nd ed. St Louis, MO: Elsevier Inc; 2007:476-478.
6. Bersenas A, Mathews K, Allen D, et al. Effects of ranitidine, famotidine, pantoprazole, and omeprazole on intragastric pH in dogs. Am J Vet Res 2005;66:425-431.
7. Abelo A, Eriksson UG, Karlsson MO, et al. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. J Pharmacol Exp Ther 2000;295:662-669.
8. Abelo A, Holstein B, Eriksson UG, et al. Gastric acid secretion in the dog: A mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole. J Pharmacokinet Pharmacodyn 2002;29:365-382.
9. Rudholm T, Hellstrom P, Theodorsson E, et al. Bravo capsule system optimizes intragastric pH monitoring over prolonged time: Effects of ghrelin on gastric acid and hormone secretion in the rat. World J Gastroenterol 2008;14:6180-6187.
10. Yamaguchi T, Seza A, Odaka T, et al. Placement of the Bravo wireless pH monitoring capsule onto the gastric wall under endoscopic guidance. Gastrointest Endosc 2006;63:1046-1050.
11. Peters A, Vickers A. The characterization of preclinical research dogs using a combination of pH monitoring and gamma scintigraphy. Delivery Tech 2006;6:50-53.
12. Sagawa K, Li F, Liese R, et al. Fed and fasted gastric pH and gastric residence time in conscious Beagle dogs. J Pharm Sci 2009;98:2494-2500.
13. Poulsen KP, Smith GW, Davis JL, et al. Pharmacokinetics of oral omeprazole in llamas. J Vet Pharmacol Ther 2005;28:539-543.
14. Mela GS, Savarino V, Vigneri S. Optimizing the information obtained from continuous 24-hour gastric pH monitoring. Am J Gastroenterol 1992;87:961-966.
15. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 2001;15:355-370.
16. Williamson KK, Willard MD, Payton ME, et al. Efficacy of omeprazole versus high-dose famotidine for prevention of exercise-induced gastritis in racing Alaskan sled dogs. J Vet Intern Med 2010;24:285-288.
17. Lui CY, Amidon GL, Berardi RR, et al. Comparison of gastrointestinal pH in dogs and humans: Implications on the use of the Beagle dog as a model for oral absorption in humans. J Pharm Sci 1986;75:271-274.
18. Yamada I, Haga K. Measurement of gastric pH during digestion of a solid meal in dogs. Chem Pharm Bull (Tokyo) 1990;38:1755-1756.
19. Akimoto M, Nagahata N, Furuya A, et al. Gastric pH profiles of Beagle dogs and their use as an alternative to human testing. Eur J Pharm Biopharm 2000;49:99-102.
20. Clary EM, Manson RJ, Lagoo S, et al. Percutaneous cervical oesophageal cannulation in the dog for the performance of prolonged oesophageal pH and manometric studies. Lab Anim 2005;39:435-441.
21. Pandolfino JE, Schreiner MA, Lee TJ, et al. Bravo capsule placement in the gastric cardia: A novel method for analysis of proximal stomach acid environment. Am J Gastroenterol 2005;100:1721-1727.
22. Bueno L, Fioramonti J, Ruckebusch Y. Gastric pH changes associated with duodenal motility in fasted dogs. J Physiol 1981;316:319-325.
23. Fackler WK, Vaezi MF, Richter JE. Ambulatory gastric pH monitoring: Proper probe placement and normal values. Aliment Pharmacol Ther 2001;15:1155-1162.
24. Chang JH, Choi MG, Yim DS, et al. A novel placement method of the Bravo wireless pH monitoring capsule for measuring intragastric pH. Dig Dis Sci 2009;54:578-585.
25. United States Pharmacopeia Pharmaceutical Compounding - Nonsterile Preparations. USP 32 NF 27, General Chapter <795>. Rockville, MD: United States Pharmacopeia; 2009:314-318.
26. Williamson KK, Willard MD, McKenzie EC, et al. Efficacy of famotidine for the prevention of exercise-induced gastritis in racing Alaskan sled dogs. J Vet Intern Med 2007;21:924-927.
27. Davis MS, Willard MD, Nelson SL, et al. Efficacy of omeprazole for the prevention of exercise-induced gastritis in racing Alaskan sled dogs. J Vet Intern Med 2003;17:163-166.